Literature DB >> 26194760

The challenges of modelling antibody repertoire dynamics in HIV infection.

Shishi Luo1, Alan S Perelson2.   

Abstract

Antibody affinity maturation by somatic hypermutation of B-cell immunoglobulin variable region genes has been studied for decades in various model systems using well-defined antigens. While much is known about the molecular details of the process, our understanding of the selective forces that generate affinity maturation are less well developed, particularly in the case of a co-evolving pathogen such as HIV. Despite this gap in understanding, high-throughput antibody sequence data are increasingly being collected to investigate the evolutionary trajectories of antibody lineages in HIV-infected individuals. Here, we review what is known in controlled experimental systems about the mechanisms underlying antibody selection and compare this to the observed temporal patterns of antibody evolution in HIV infection. We describe how our current understanding of antibody selection mechanisms leaves questions about antibody dynamics in HIV infection unanswered. Without a mechanistic understanding of antibody selection in the context of a co-evolving viral population, modelling and analysis of antibody sequences in HIV-infected individuals will be limited in their interpretation and predictive ability.
© 2015 The Author(s) Published by the Royal Society. All rights reserved.

Entities:  

Keywords:  HIV; evolution; immunology

Mesh:

Substances:

Year:  2015        PMID: 26194760      PMCID: PMC4528423          DOI: 10.1098/rstb.2014.0247

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  28 in total

Review 1.  Germinal centers.

Authors:  Gabriel D Victora; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.

Authors:  Ashley M Trama; M Anthony Moody; S Munir Alam; Frederick H Jaeger; Bradley Lockwood; Robert Parks; Krissey E Lloyd; Christina Stolarchuk; Richard Scearce; Andrew Foulger; Dawn J Marshall; John F Whitesides; Thomas L Jeffries; Kevin Wiehe; Lynn Morris; Bronwen Lambson; Kelly Soderberg; Kwan-Ki Hwang; Georgia D Tomaras; Nathan Vandergrift; Katherine J L Jackson; Krishna M Roskin; Scott D Boyd; Thomas B Kepler; Hua-Xin Liao; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2014-08-13       Impact factor: 21.023

Review 4.  T follicular helper cells and HIV/SIV-specific antibody responses.

Authors:  Constantinos Petrovas; Richard A Koup
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

Review 5.  Modeling sequence evolution in acute HIV-1 infection.

Authors:  Ha Youn Lee; Elena E Giorgi; Brandon F Keele; Brian Gaschen; Gayathri S Athreya; Jesus F Salazar-Gonzalez; Kimmy T Pham; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Beatrice H Hahn; George M Shaw; Bette T Korber; Tanmoy Bhattacharya; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-08-04       Impact factor: 2.691

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

8.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

9.  Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies.

Authors:  Shenshen Wang; Jordi Mata-Fink; Barry Kriegsman; Melissa Hanson; Darrell J Irvine; Herman N Eisen; Dennis R Burton; K Dane Wittrup; Mehran Kardar; Arup K Chakraborty
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

10.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more
  3 in total

Review 1.  The evolution within us.

Authors:  Sarah Cobey; Patrick Wilson; Frederick A Matsen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

2.  Evolution during primary HIV infection does not require adaptive immune selection.

Authors:  David A Swan; Morgane Rolland; Joshua T Herbeck; Joshua T Schiffer; Daniel B Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 11.205

3.  Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections.

Authors:  Armita Nourmohammad; Jakub Otwinowski; Joshua B Plotkin
Journal:  PLoS Genet       Date:  2016-07-21       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.